Immunohistochemistry for CDX2, MUC2, MUC5AC, MUC6, MUC1, HER2, ß-catenin, and p53, as well as next-generation sequencing of 110 tumor-related genes (AmoyDx® Comprehensive Panel), were performed. This evidence concerns the gene MUC1 and neoplasm.